Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: February 17, 2026 | Boston Scientific Corporation | |
|---|
| By: | /s/ Jonathan Monson |
| Jonathan Monson |
| Executive Vice President and Chief Financial Officer |
| (duly authorized officer and principal financial officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Dated: February 17, 2026 | By: | /s/ Jonathan Monson |
|---|
| Jonathan Monson |
| Executive Vice President and Chief Financial Officer |
| (Principal Financial Officer) |
| Dated: February 17, 2026 | By: | /s/ Michael F. Mahoney |
|---|
| Michael F. Mahoney |
| Director, Chairman of the Board, President and Chief Executive Officer |
| (Principal Executive Officer) |
| Dated: February 17, 2026 | By: | /s/ Emily M. Woodworth |
|---|
| Emily M. Woodworth |
| Senior Vice President, Global Controller and Chief Accounting Officer |
| (Principal Accounting Officer) |
| Dated: February 17, 2026 | By: | /s/ Yoshiaki Fujimori |
|---|
| Yoshiaki Fujimori |
| Director |
| Dated: February 17, 2026 | By: | /s/ David Habiger |
|---|
| David Habiger |
| Director |
| Dated: February 17, 2026 | By: | /s/ Edward J. Ludwig |
|---|
| Edward J. Ludwig |
| Director |
| Dated: February 17, 2026 | By: | /s/ Jessica L. Mega |
|---|
| Jessica L. Mega |
| Director |
| Dated: February 17, 2026 | By: | /s/ Susan E. Morano |
|---|
| Susan E. Morano |
| Director |
| Dated: February 17, 2026 | By: | /s/ Cheryl Pegus |
|---|
| Cheryl Pegus |
| Director |
| Dated: February 17, 2026 | By: | /s/ John E. Sununu |
|---|
| John E. Sununu |
| Director |
| Dated: February 17, 2026 | By: | /s/ David S. Wichmann |
|---|
| David S. Wichmann |
| Director |
| Dated: February 17, 2026 | By: | /s/ Ellen M. Zane |
|---|
| Ellen M. Zane |
| Director |
Schedule II
VALUATION AND QUALIFYING ACCOUNTS
| Description (in millions) | Balance at Beginning of Year | Credit loss exposure(1) | Write-offs(2) | Balance atEnd of Year |
|---|
| Year Ended December 31, 2025: |
|---|
| Allowances for credit losses | $109 | 56 | (33) | $132 |
|---|
| Year Ended December 31, 2024: |
|---|
| Allowances for credit losses | $110 | 41 | (43) | $109 |
|---|
| Year Ended December 31, 2023: |
|---|
| Allowances for credit losses | $109 | 50 | (48) | $110 |
|---|
(1) We record credit loss reserves to Allowance for credit losses when we establish Trade accounts receivable if credit losses are expected over the asset's contractual life. Subsequent credit loss reserves are recorded when deemed uncollectible. Amounts shown within credit loss exposure above were established through selling, general and administrative expense.
(2) Represents actual write-offs of uncollectible accounts.
